Boenning & Scattergood Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Neutral
More News related to ONXX
- Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
- Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
- Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
Boenning & Scattergood initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with a Neutral.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
